dsm-firmenich Venturing is the corporate venture arm of the nutrition and health group dsm-firmenich. In the psychedelic space it is an investor in Octarine Bio, the Danish synthetic-biology company producing pharmaceutical-grade psilocybin and other neuroactive compounds via engineered yeast fermentation.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage focus is not listed yet. Psychedelic-market posture: Psychedelic-Adjacent Focus.
Public Portfolio Examples
- Octarine BioPre-Series A funding - €4.35 million - Nov 8, 2023
Created from documented participation in 2 Octarine Bio financing rounds (pre-Series A 2023, Series A close 2026). Profile details beyond documented deals are unverified.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Stage focus is not listed yet.
Investment Focus Areas
Focus areas are not listed yet.
Recorded Investments
Jan 22, 2026
Series A (close) - €12.8 million total Series A (incl. €5 million new capital added Jan 2026)
Danish biotech Octarine Bio closes €12.8 million Series A for sustainable pigments